Presentation and Status in Health Basket
| Presentation | Basket | Yarpa | Pharmasoft |
|---|---|---|---|
|
Tablets 30 X 0.5 mg |
|
32512 | 5594 |
|
Tablets 30 X 1 mg |
|
32513 | 5595 |
Dosage
Compensated liver disease: Nucleoside naive patients: 0.5 mg, once daily, with or without food. Lamivudine-refractory patients: 1 mg once daily, without food.
Decompensated liver disease: 1 mg once daily, without food. For patients with lamivudine-refractory hepatitis B.
Indications
Treatment of chronic hepatitis B virus (HBV) infection in adults with: Compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis. Decompensated liver disease. For both compensated and decompensated liver disease, this indication is based on clinical trial data in nucleoside naive patients with HBeAg positive and HBeAg negative HBV infection. With respect to patients with lamivudine-refractory hepatitis B.
Contra-Indications
Known hypersensitivity to the active ingredient or to any of the other ingredients included in this medicine. Breastfeeding.
Special Precautions
See prescribing information for full details.
Side Effects
See prescribing information for full details.
Drug interactions
See prescribing information for full details.
Pregnancy and Lactation
See prescribing information for full details.
Overdose
See prescribing information for full details.
Important notes
See prescribing information for full details.
